Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Joseph Haas
Yutiq, for posterior uveitis, will compete with two existing steroid products and should launch during the first quarter of 2019. EyePoint’s Dexycu, although approved in February, is still in scale-up and probably will launch a bit later.
Opdivo failed to meet an overall survival endpoint in a Phase III confirmatory study in small-cell lung cancer. But several analysts think Bristol will keep the SCLC labeling obtained in August due to lack of treatment options for these patients.
Investors are keen to see how J&J's Remicade is holding up to biosimilar competition, especially now that Zytiga generics are on the way. Novartis is likely to play up the potential for new launches like siponimod in multiple sclerosis and Aimovig in migraine, while Roche is expected to continue delivering strong performance for core brands and expansion plans for Tecentriq.
With partner CCHN, Alvotech will help finance construction of a biologics facility in Changchun, China. Novartis will work with Cellular Biomedicine to produce Kymriah for China, and will gain access to its CAR-T platform.
Celgene estimates 80% of moderate-to-severe plaque psoriasis patients experience the disease in their scalps, meaning positive data in this indication could broaden the market opportunity for Otezla substantially. Novartis’ Cosentyx got scalp psoriasis added to its US label in February.
Approved two months after Alnylam’s Onpattro, Tegsedi is priced almost identically in the same hATTR indication. Ionis affiliate Akcea hopes weekly subcutaneous administration will provide convenience benefit compared to I.V. Onpattro.